CUREVAC N.V. news, videos and press releases - Page 5
For more news please use our advanced search feature.
CUREVAC N.V. - More news...
CUREVAC N.V. - More news...
- DGAP-News: CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update
- DGAP-News: CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
- CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
- Curevac Announces Financial Results For The First Quarter Of 2022 And Provides Business Update
- DGAP-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update
- CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update
- DGAP-News: CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022
- CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022
- DGAP-News: CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study
- CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study
- DGAP-News: CureVac and GSK Enter into Pandemic Preparedness Contract with German Government
- CureVac and GSK Enter into Pandemic Preparedness Contract with German Government
- DGAP-News: CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
- CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
- DGAP-News: CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)
- CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)
- DGAP-News: CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
- CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
- DGAP-News: CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry
- CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry
- dievini and the Federal Republic of Germany Amend Shareholders’ Agreement Regarding Investments in CureVac N.V.
- CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update
- DGAP-News: CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update
- DGAP-News: CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine
- CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine
- DGAP-News: CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response
- CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response
- DGAP-News: CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
- CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
- DGAP-News: CureVac Streamlines European Network for mRNA Product Manufacturing
